Argenx, which is developing antibody therapies for rare autoimmune diseases and cancer, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Breda, Netherlands-based company was founded in 2008 and booked $18 million in revenue for the 12 months ended December 31, 2016. It plans to list on the Nasdaq under the symbol ARGX. Argenx filed confidentially on March 1, 2017. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
